Andrew C. Orth
President, CEO & DirectorDr. Andrew C. Orth, also known as Andy, M.B.A., is President, CEO & Director of City Therapeutics, Inc. sine December 2024. Dr. Orth served as Executive Vice President at Krystal Biotech, Inc. until August 2, 2023. He had been Chief Commercial Officer at Krystal Biotech, Inc. since May 3, 2021 until August 2, 2023. He joined Krystal Biotech, Inc. on May 3, 2021. Dr. Orth served as Senior Vice President, Head of U.S. at Alnylam Pharmaceuticals, Inc. from 2016 to 2021. He served as Vice-President of Commercial Practice at Alnylam Pharmaceuticals, Inc. Dr. Orth serves as Managing Director of PlanOrg Informatik GmbH. He has deep experience in commercial operations, analytics and finance from across the biopharma industry. He joined Alnylam in 2016 following years with Biogen, as the Vice-President of Global Decision Support within Biogen’s Global Commercial Strategy function from 2009 to 2016. He held the role of Vice-President of US Commercial Effectiveness & Operations for Biogen’s US business as it grew from two to six products across multiple therapeutic areas. Prior to Biogen, he was an Executive Director with Russell Reynolds Associates. Previously, he also held the positions of Vice-President, Finance and Global Controller for Genzyme’s renal business and Director of Commercial Finance for Amgen’s U.S. inflammation business. He received his B.S. in Philosophy and Psychology from the University of Wisconsin and his MBA from the Johnson Graduate School of Management at Cornell University.
Positions
- Company NameCity Therapeutics, Inc.Stock CodeCTYPositionPresident, CEO & Director
